Ultragenyx Pharmaceutical Inc. buy Royal Bank of Canada
Start price
26.09.24
/
50%
€49.00
Target price
26.09.25
€69.10
Performance (%)
-49.39%
End price
27.09.25
€24.80
Summary
This prediction ended on 27.09.25 with a price of €24.80. Massive losses of -49.39% were the result for the BUY prediction by Royal_Bank_of_Canada. Royal_Bank_of_Canada has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. | -7.895% | -7.895% | -34.579% |
| iShares Core DAX® | -0.793% | 4.201% | 19.951% |
| iShares Nasdaq 100 | -2.376% | 0.857% | 4.704% |
| iShares Nikkei 225® | -2.701% | -0.147% | 12.609% |
| iShares S&P 500 | -1.689% | 1.244% | 3.144% |
Comments by Royal_Bank_of_Canada for this prediction
In the thread Ultragenyx Pharmaceutical Inc. diskutieren
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $77.00 price target on the stock.
Ratings data for RARE provided by MarketBeat
In the thread Trading Ultragenyx Pharmaceutical Inc.
Die von Royal_Bank_of_Canada gewählte maximale Laufzeit wurde überschritten
Stopped prediction by Royal_Bank_of_Canada for Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€47.00
06.11.24
06.11.24
€71.64
06.11.25
06.11.25
-42.98%
07.11.25
07.11.25
Ultragenyx Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€41.20
22.04.24
22.04.24
€72.35
22.04.25
22.04.25
-22.82%
23.04.25
23.04.25